Today, Explained Johnson & Johnson & Problems
Apr 13, 2021
Caroline Chen, a healthcare reporter at ProPublica, dives into the recent pause of Johnson & Johnson vaccinations due to rare blood clot cases. She discusses the implications this decision has on public health and vaccination efforts. The conversation also touches on how vaccine hesitancy is influenced by safety concerns, highlighting comparisons with the AstraZeneca vaccine. Chen explores potential future scenarios for COVID-19 and the critical need for clear communication to restore public trust in vaccines.
AI Snips
Chapters
Transcript
Episode notes
J&J Vaccine Pause
- The US government recommended pausing Johnson & Johnson vaccinations due to rare blood clots.
- This is after six recipients (out of millions) developed clots, one resulting in death.
CVST Rarity
- The blood clots, called cerebral venous sinus thrombosis (CVST), are extremely rare.
- Only six cases have been reported out of over 6.8 million J&J doses administered.
Post-Vaccine Symptoms
- If you experience severe headache, abdominal pain, leg pain, or shortness of breath after receiving the J&J vaccine, contact your healthcare provider.
- Standard blood clot treatment (heparin) can worsen these rare clots.